VCRE vs DUOT Comparison

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.